Development of leishmania vaccines: Predicting the future from past and present experience

Journal of Biomedical Research

Volumn 27, Issue 2, 2013, Pages 85-102

  Mutiso, Joshua Muli ^a,b   Macharia, John Chege ^a   Kiio, Maria Ndunge ^a   Ichagichua, James Maina ^a   Rikoi, Hitler ^a   Gicherub, Michael Muita ^b  

^a INSTITUTE OF PRIMATE RESEARCH   (Kenya)

^b KENYATTA UNIVERSITY   (Kenya)

Author keywords

Immune response; Immunization; Leishmania; Leishmaniasis; Vaccine

Indexed keywords

ANTIMONY; BCG VACCINE; CPG OLIGODEOXYNUCLEOTIDE; DNA VACCINE; FLUCYTOSINE; FUCOSE MANNOSE LIGAND; GAMMA INTERFERON; GELATINASE B; GLYCOCONJUGATE; GLYCOPROTEIN; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; LEISHMANIA VACCINE; LIGAND; LIPOSOME; LIVE VACCINE; NAKED DNA; NITRIC OXIDE; PARASITE ANTIGEN; PHOSPHORYL LIPID A; PROTEOPHOSPHOGLYCAN; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; SAPONIN; STIBOGLUCONATE SODIUM; SUBUNIT VACCINE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DRUG FORMULATION; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; LEISHMANIA MAJOR; LEISHMANIASIS; NONHUMAN; PARASITE CONTROL; PROTECTION; RELAPSE; SKIN LEISHMANIASIS; TH2 CELL;

EID: 84891753022     PISSN: 16748301     EISSN: None     Source Type: Journal    
DOI: 10.7555/JBR.27.20120064     Document Type: Article

References (140)

1. Dumonteil E, Jesus MRS, Javier EO, del Rosario MGM. DNA vaccines induce partial protection against Leish mania mexicana. Vaccine 2003; 21: 2161-8.
2. Vanloubbeeck Y, Jones D. The immunology of Leish mania infection and the implications for vaccine devel opment. Ann N Y Acad Sci 2004; 1026: 267-72.
3. Special program for research and training in tropical dis eases (TDR). Research to support the elimination of vis ceral leishmaniasis. Annual report 2009. World Health Organization. TDR/BL10.10 Geneva. 2010.
4. Bern C, Maguire JH, Alvar J. Complexities of assessing the disease burden attributable to leishmaniasis. PLos Negl Trop Dis 2008; 2: e313.
5. Chevalier B, Carmoi T, Sagui E, Carrette P, Petit D, De Mauleon P, et al. Report of the first cases of cutaneous leishmaniasis in East Timor. Clin Infect Dis 2000; 30: 839-40.
6. Kongkaew W, Siriarayaporn P, Leelayoova S, Supparat pinyo K, Areechokchai D, Duang-ngern P, et al. Auto chthonous visceral leishmaniasis: a report of a second case in Thailand. Southeast Asian J Trop Med Public Health 2007; 38: 8-12.
7. Rose K, Curtis J, Baldwin T, Mathis A, Kumar B, Sak thianandeswaren A, et al. Cutaneous leishmaniasis in red kangaroos: Isolation and characterization of the causa tive organisms. Int J Parasitol 2004; 34: 655-64.
8. World Health Organization (WHO). Control of Leish maniasis. Report by the Secretariat; Sixth World Health Assembly. A60/10 Provisional agenta item 12.3. 2007.
9. Croft S, Sundar S, Fairlamb H. Drug resistance in leish maniasis. Clin Microbiol Rev 2006; 19: 111-6.
10. Rodriguez-Cortes A, Ojeda A, Lopez-Fuertez L, Timón M, Altet L, Solano-Gallego L, et al. Vaccination with plasmid DNA encoding KMPII, TRYP, LACK, and GP63 does not protect dogs against Leishmania infan tum experimental challenge. Vaccine 2007; 25: 7962-71.
11. Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alex ander B, Brooker S. Cutaneous leishmaniasis. Lancet Infect Dis 2007; 7: 581-96.
12. Dantas-Torres F. Canine leishmaniosis in South Ameri ca. Parasit Vect 2009; 2(S1): 1.
13. Postigo JAR. Leishmaniasis in the World Health Organi zation Eastern Mediterranean Region. Intern J Antimi crob Agents 2010; 36(S): 62-5.
14. Stanley AC, Engwerda CR. Balancing immunity and pa thology in visceral leishmaniasis. Immunol Cell Biol 2007; 85: 138-47.
15. Reiner SL, Locksley MR. The regulation of immunity to Leishmania major. Ann Rev Immunol 1995; 13: 151-77.
16. Stern JJ, Oca MJ, Rubin BY, Anderson SL, Murray HW. Role of L3T4+ and Lyt-2+ cells in experimental visceral leishmaniasis. J Immunol 1988; 140: 3971-77.
17. Kharazmi A, Kemp K, Ismail A, Gasim S, Gaafar A, Kurtzhals JA, et al. T-cell response in human leishma niasis. Immunology Letters 1999; 65: 105-8.
18. Melby PC, Anstead GM. Immune responses to protozoa. In: Clinical immunology: principles and practices. Rich RR, Fleisher TA, Shearer WT, Kotzin BL, Schroder Jr HW, Editors, 2nd Edition. Mosby Intern Limited: Mos by, 2001; 29: 1-29.13.
19. Stager S, Smith DF, Kaye PM. Immunization with a re combinant stage-regulated surface protein from Leish mania donovani induces protection against visceral leishmaniasis. J Immunol 2000; 165: 7064-71.
20. Mizbani A, Taheri T, Zahedifard F, Taslimi Y, Azizi H, Azadmanesh K, et al. Recombinant Leishmania taren tolae expressing the A2 virulence gene as a novel can didate vaccine against visceral leishmaniasis. Vaccine 2010; 28: 53-62.
21. Lima LUVR, Carneiro LA, Campos MB, Chagas EJ, Laurenti MD, Corbett CEP, et al. Canine visceral leish maniasis due to Leishmania (L.) infantum chagasi in Amazonian Brazil: comparison of the parasite density from the skin, lymph node and visceral tissues between symptomatic and asymptomatic, seropositive dogs. Rev Instituto Med Trop Sao Paulo 2010; 52: 259-65.
22. Garg R, Dube A. Animal models for vaccine studies for visceral leishmaniasis. Indian J Med Res 2006; 123: 439-54.
23. Nylen S, Gautam S. Immunological perspectives of leishmaniasis. J Global Infect Dis 2010; 2: 135-46.
24. Khamesipour A, Rafati S, Davoudi N, Maboudi F, Modabber F. Leishmaniasis vaccine candidates for devel opment: A global overview. Indian J Med Res 2006; 123: 423-38.
25. Coler RN, Reed S. Second generation vaccines against leishmaniasis. Trend Parasitol 2005; 21: 244-9.
26. Bray RS, Modabber F. The history of leishmaniasis. In: Gilles HM, editor. Protozoal Diseases. New York & London: Hodder Arnold Publisher: 2000; 414-9.
27. Senekji HA, Beattie CP. Artificial infection and immu nization of 368 men with cultures of L. tropica. Trans R Soc Trop Med Hyg 1941; 369: 415-9.
28. Greenblatt CL. The present and future of vaccination for cutaneous leishmaniasis. In: Mizrahi A, Hertman I, Klingberg MA, Kohn A, editors. New developments with human and veterinary vaccine. New York: Alan R Liss Inc, 1980; 259-85.
29. Handman E. Leishmaniasis: current status of vaccine de velopment. Clin Microbiol Rev 2001; 14: 229-43.
30. Breton M, Tremblay M, Ouellette M, Papadopoulou B. Live non-pathogenic vectors as a candidate vaccine against visceral Leishmaniasis. Infect Immun 2005; 73: 6372-82.
31. Roberts MTM. Current understandings on the immunol ogy of leishmaniasis and recent developments in pre vention and treatment. British Med Bullet 2006; 75/76: 115-30.
32. Sergiev VP. Control and prophylaxis of cutaneous leish maniasis in the middle Asia republics of the former USSR. Bull Soc Fran Parasit 1992; 10: 183-4.
33. Gafurov IM. Experience in controlling and preventing zoonotic cutaneous leishmaniasis in Uzbekistan. Med Parazitol (Mosk) 1999; 1: 58-9.
34. Genaro O, de Toledo VP, Da Costa CA, Hermeto MV, Afonso LC, Mayrink W. Vaccine for prophylaxis and immunotherapy. Brazil. Clin Dermatol 1996; 14: 503-12.
35. Velez ID, del Pilar-Agudelo S, Arbelaez MP, Gilchrist K, Robledo SM, Puerta JA, et al. Safety and immuno genicity of a killed Leishmania (L.) amazonensis vac cine against cutaneous leishmaniasis in Colombia: a randomized controlled trial. Trans R Soc Trop Med Hyg 2000; 94: 698-703.
36. Velez ID, Gilchrist K, Arbelaez MP, Rojas CA, Puerta JA, Antunes CM, et al. Failure of a killed Leishmania amazonensis vaccine against American cutaneous leish maniasis in Colombia. Trans R Soc Trop Med Hyg 2005; 99: 593-8.
37. Armijos RX, Weigel MM, Calvopina M, Hidalgo A, Cevallos W, Correa J. Safety, immunogenecity, and ef ficacy of an autoclaved Leishmania amazonensis vac cine plus BCG adjuvant against New World cutaneous leishmaniasis. Vaccine 2004; 22: 1320-6.
38. Convit J, Castellanos PL, Rondón AJ, Pinardi ME, Ulrich M, Castés M, et al. Immunotherapy versus chemo therapy in localized cutaneous leishmaniasis. Lancet 1987; 1: 401-5.
39. Jackson MP, Pinto J, da Costa CA, Genaro O, Marques MJ, Modabber F, et al. Immunochemotherapy for cu taneous leishmaniasis: a controlled trial using killed Leishmania amazonensis vaccine plus antimonial. Inter J Dermatol 2002; 41: 73-8.
40. Convit J, Ulrich M, Zerpa O, Aranzazu N, Valera M, Villaroel H, et al. Immunotherapy of American cutane ous leishmaniasis in Venezuela, 1990 to 1999. Trans R Soc Trop Med Hyg 2003; 97: 1-4.
41. Armijos RX, Weigel MM, Aviles H, Maldonado R, Racines J. Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-up. J Infect Dis 1998; 177: 1352-7.
42. Bahar K, Dowlati Y, Shidani B, Alimohammadian MH, Khamesipour A, Ehsasi S, et al. Comparative safety and immunogenicity trial of two killed Leishmania major vaccines with or without BCG in human volunteers. Clin Dermatol 1996; 14: 489-95.
43. Dowlati Y, Ehsasi S, Shidani B, Bahar K. Stepwise safety trial of a killed Leishmania vaccine in Iran. Clin Der matol 1996; 14: 497-502.
44. Momeni AZ, Jalayer T, Emamjomeh M, Khamesipour A, Zicker F, Labaf-Ghasemi R, et al. A randomized, double blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine 1999; 17: 466-72.
45. Sharifi I, FeKri A, Aflatonian M, Khamesipour A, Nadim A, Mousavi MRA, et al. Randomized vaccine trial of a single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 1998; 351: 1540-3.
46. Khalil EA, El Hassan AM, Zijlstra EE, Mukhtar MM, Ghalib HW, Musa B, et al. Autoclaved Leishmania ma jor vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Su dan. Lancet 2000; 356: 1565-9.
47. Dube A, Sharma P, Srivastava JK, Misra A, Naik S, Katiyar JC. Vaccination of langur monkeys (Presbytis entellus) against Leishmania donovani with autoclaved L. major plus BCG. Parasitol 1998; 116: 219-21.
48. Kenney RT, Sacks DL, Sypek JP, Vilela L, Gam AA, Davis KE. Protective immunity using recombinant hu man IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J Immunol 1999; 163: 4481-8.
49. Gicheru MM, Olobo JO, Anjili CO, Orago AS, Modabber F, Scott P. Vervet Monkeys vaccinated with killed Leishmania major parasites and Interleukin-12 develop a type 1 immune response but are not protected against challenge infection. Infect Immun 2001; 69: 245-51.
50. Misra A, Anuradha D, Bindu S, Preeti S, Srivastava JK, Katiyar JC. Successful vaccination against Leishmania donovani infection in Indian langur using alum-precip itated autoclaved Leishmania major with BCG. Vaccine 2001; 19: 3485-92.
51. Mohebalia M, Khamesipour A, Mobedi I, Zareia Z, Hashemi-Fesharki R. Double blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-shahr district I.R. Iran. Vac cine 2004; 22: 4097-100.
52. Kamil AA, Khalil EAG, Musa AM, Modabber F, Mukhtar MM, Ibrahim ME, et al. Alum-precipitated autoclaved Leishmania major plus bacille Calmette-Guérrin, a candidate vaccine for visceral leishmaniasis: safety, skin-delayed type hypersensitivity response and dose finding in healthy volunteers. Trans R Soc Trop Med Hyg 2003; 97: 365-8.
53. Khalil EAG, Nahla B, Ayed NB, Musa AM, Ibrahim ME, Mukhtar MM, et al. Dichotomy of protective cellular immune responses to human visceral leishmaniasis. Clin Exp Immunol 2005; 140: 349-53.
54. Mutiso JM, Macharia JC, Kariuki TM, Gicheru MM. (2009) Montanide ISA 720 is more effective than BCG as an adjuvant for Leishmania killed vaccine in BALB/c mice. IJIB 2009; 7: 107-16.
55. Mutiso JM, Macharia JC, Taracha E, Gicheru MM. Leishmania donovani whole cell antigen delivered with adjuvants protects against visceral leishmaniasis in vervet monkeys (Chlorocebus aethiops). J Biomed Res 2012; 26: 8-16.
56. Musa AM, Khalil EA, Mahgoub FA, Elgawi SH, Mo dabber F, Elkadaru AE, et al. Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment. Trans Roy Soc Trop Med Hyg 2008; 102: 58-63.
57. Palatnik-de-Sousa CB, Dutra HS, Borojevic R. Leishma nia donovani surface glycoconjugate GP63 is the major immunogen component of the fucose-mannose ligand (FML). Acta Trop 1993; 53: 59-72.
58. Palatnik-de-Sousa CB, Paraguai de Souza E, Gomes EM, Borojevic R. Experimental murine Leishmania donovani infection: Immunoprotection by the fucose-mannose ligand (FML). Braz J Med Biol Res 1994; 27: 547-51.
59. Borja-Cabrera GP, Correia Pontes NN, da Silva VO, Paraguai de Sousa E, Santos WR, Gomes EM. Long lasting protection against canine kala-azar using FML-Quil A saponin vaccine in an endemic area of Brazil. Vaccine 2002; 20: 3277-84.
60. Afrin F, Ali N. Adjuvanticity and protective immunity elicited by Leishmania donovani antigens encapsulated in positively charged liposomes. Infect Immun 1997; 65: 2371-7.
61. Tonui WK, Mejia JS, Hochberg L, Mbow ML, Ryan JR, Chan AST, et al. Immunization with Leishmania major exogenous antigens protects susceptible BALB/c mice against challenge infection with L. major. Infect Immun 2004;72:5654-61.
62. Sharma SK, Dube A, Nadeem A, Khan S, Saleem I, Garg R, et al. Non-PC liposome entrapped promastigote an tigens elicit parasite specific CD8+ and CD4+ T-cell immune response and protect hamsters against visceral leishmaniasis. Vaccine 2006; 24: 1800-10.
63. Shargh VH, Jaafari MR, Khamesipour A, Jaafari I, Jalali SA, Abbasi A, et al. Liposomal SLA co-incorporated with PO CpG ODNs or PS CpG ODNs induce the same protection against the murine model of leishmaniasis. Vaccine 2012; 30: 3957-64.
64. Liu MA, Wahren B, Hedestam GBK. DNA vaccines: Recent developments and future possibilities. Human Gene Therapy 2006; 17: 1051-61.
65. Kedzierski L. Leishmaniasis Vaccine: Where are we to day? J Glob Infect Dis 2010; 2: 177-85.
66. Olobo JO, Anjili CO, Gicheru MM, Mbati PA, Kariuki TM, Githure JI, et al. Vaccination of vervet monkeys against cutaneous leishmaniasis using recombinant Leishmania major surface glycoprotein (gp63). Vet Parasitol 1995; 60: 199-212.
67. Jaafari MR, Badiee A, Khamesipour A, Samiei A, Soroush D, Kheiri MT, et al. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major sur face glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome. Vaccine 2007; 25: 6107-17.
68. Russo DM, Burns JM, Carvalho EM, Armitage RJ, Grabstein KH, Button LL, et al. Human T cell responses to gp63, a surface antigen of Leishmania. J Immunol 1991; 147: 3575-80.
69. Bhowmick S, Ravindran R, Ali N. Gp63 in stable cati onic liposemes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania do novani. Infect Immun 2008; 76: 1003-15.
70. Badiee A, Jaafari MR, Khamesipour A, Samieia A, Soroush D, Kheiric MT, et al. Enhancement of immune response and protection in BALB/c mice immunized with liposomal recombinant major surface glycoprotein of Leishmania (rgp63): the role of bilayer composition. Colloids Surf B Biointerfaces 2009; 74: 37-44.
71. Mazumder S, Maji M, Das A, Ali N. Potency, efficacy and durability of DNA/DNA, DNA/protein and protein/ protein based vaccination using gp63 against Leish mania donovani in BALB/c mice. PLoS One 2011; 6: e14644.
72. McMahon-Pratt D, Traub-Cseko Y, Lohman KL, Rogers DD, Beverley SM. Loss of the GP46/M-2 surface membrane glycoprotein gene family in the Leishmania braziliensis complex. Mol Biochem Parasitol 1992; 50: 151-60.
73. Handman E, Osborn AH, Symons F, van Driel R, Cappai R. The Leishmania promastigote surface antigen 2 complex is differentially expressed during the parasite life cycle. Mol Biochem Parasitol 1995; 74: 189-200.
74. Sjolander A, Baldwin TM, Curtis JM, Bengtsson LK, Handman E. Vaccination with recombinant parasite surface antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection. Vaccine 1998; 16: 2077-84.
75. Kedzierski L, Montgomery J, Bullen D, Curtis J, Gardiner E, Jimenez-Ruiz A, et al. A leucine-rich repeat motif of Leishmania parasite surface antigen 2 binds to macrophages through the complement receptor 3. J Im munol 2004; 172: 4902-6.
76. Samant M, Gupta R, Kumari S, Misra P, Khare P, Kushawaha PK. Immunization with the DNA-encoding N-terminal domain of proteophosphoglycan of Leish mania donovani generates Th1-type immunoprotective response against experimental visceral leishmaniasis. J Immunol 2009; 183: 470-9.
77. Chávez-Fumagalli MA, Costa MA, Oliveira DM, Ramírez L, Costa LE, Duarte MC, et al. Vaccination with the Leishmania infantum ribosomal proteins induces protection in BALB/c mice against Leishmania chagasi and Leishmania amazonensis challenge. Microbes Infect 2010; 12(12-13): 967-77.
78. Ramírez L, Iborra S, Cortés J, Bonay P, Alonso C, Barral-Netto M. BALB/c mice vaccinated with Leishma nia major ribosomal proteins extracts combined with CpG oligodeoxynucleotides become resistant to disease caused by a secondary parasite challenge. J Biomed Biotechnol 2010; 181690.
79. Masina S, Gicheru MM, Demotz SO, Fasel NJ. Protec tion against cutaneous leishmaniasis in outbred Vervet Monkeys, using a recombinant Histone-1 antigen. J In fect Dis 2003; 188: 1250-7.
80. Mougneau E, Altare F, Wakil AE, et al. Expression clon ing of a protective Leishmania antigen. Science 1995; 268: 563-6.
81. Launois P, Maillard I, Pingel S, Swihart KG, Xénarios I, Acha-Orbea H, et al. IL-4 rapidly produced by V beta 4 V alpha 8 CD4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice. Immun 1997; 6: 541-9.
82. Gurunathan S, Sacks DL, Brown DR, Reiner SL, Charest H, Glaichenhaus N, et al. Vaccination with DNA encod ing the immunodominate LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med 1997; 186: 1137-47.
83. Julia V, Rassoulzadegan M, Glaichenhaus N. Resistance to Leishmania major induced by tolerance to a single antigen. Science 1996; 18: 421-3.
84. Melby PC, Yang J, Zhao W, Perez LE, Cheng J. Leish mania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect Immun 2001; 69: 4719-25.
85. Jensen KD, Sercarz EE, Gabaglia CR. Altered peptide ligands can modify the Th2 cell response to the im munodominant 161-175 peptide of LACK (Leishmania homolog for the receptor of activated C kinase). Mol Immunol 2009; 46: 366-74.
86. Dey A, Sharma P, Redhu N, Singh S. Kinesin motor do main of Leishmania donovani as a future vaccine candi date. Clin Vaccine Immunol 2008; 15: 836-42.
87. Choudhury R, Das P, Bhaumik SK, De T, Chakraborti T. In situ immunolocalization and stage-dependent expres sion of a secretory serine protease in Leishmania do novani and its role as a vaccine candidate. Clin Vaccine Immunol 2010; 17: 660-7.
88. Choudhury R, Das P, De T, Chakraborti T. 115 kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-γ induced down-regulation of TNF-α mediated MMP-9 activity. Immunobiol 2012; [Epub ahead of print] PMID: 22440312.
89. Goto Y, Bhatia A, Raman VS, Vidal SE, Bertholet S, Coler RN. Leishmania infantum sterol 24-c-methyl transferase formulated with MPL-SE induces cross protection against L. major infection. Vaccine 2009; 27: 2884-90.
90. Goto Y, Bogatzki LY, Bertholet S, Coler RN, Reed SG. Protective immunization against visceral leishmaniasis using Leishmania sterol 24-c-methyltransferase formu lated in adjuvant. Vaccine 2007; 25: 7450-8.
91. Skeiky YA, Coler RN, Brannon M, Stromberg E, Greeson K, Crane RT, et al. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine 2002; 20: 3292-303.
92. Gradoni L, Manzillo VFV, Pagano A, Piantedosi D, de Luna R, Gramiccia M, Scalone A, et al. Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals. Vac cine 2005; 23: 5245-51.
93. Coler RN, Goto Y, Lisa B, Raman V, Reed SG. Leish-111f, a recombinant polyprotein vaccine that protects against visceral leishmaniasis by elicitation of CD4+ T cells. Infect Immunol 2007; 75: 4648-54.
94. Miret J, Nascimento E, Sampaio W, França JC, Fujiwara RT, Vale A, et al. Evaluation of an immuno-chemother apeutic protocol constituted of N-methyl meglumine an timoniate (Glucantime) and the recombinant Leish-110f + MPL-SE vaccine to treat canine visceral leishmaniasis. Vaccine 2008; 26: 1585-94 .
95. Wahren B. Gene vaccines. Immunotechnol 1996; 2: 77-83.
96. Alarcon JB, Waine GW, McManus DP. DNA vaccines: technology and application as anti-parasite and anti microbial agents. Adv Parasitol 1999; 42: 344-410.
97. Seder RA, Gurunathan S. DNA vaccines-designer vac cines for the 21st century. N Engl J Med 1999; 341: 277-8.
98. Gurunathan S, Wu C, Freidag BL, Seder RA. DNA vac cines: a key for inducing long-term cellular immunity. Curr Opin Immunol 2000; 12: 442-7.
99. Eric D. DNA Vaccines again protozoan parasites: Ad vances and challenges. J Biomed Biotechnol 2007; 10: 1155-66.
100. Handman E, Noormohammadi AH, Curtis JM, Baldwin T, Sjölander A. Therapy of murine cutaneous leishma niasis by DNA vaccination. Vaccine 2000; 18: 3011-7.
101. Walker PS, Scharton-Kersten T, Rowton ED, Hengge U, Bouloc A, Udey MC, et al. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis. Hum Gene Ther 1998; 9: 1899-907.
102. Carter K, Henriquez F, Campbell S, Roberts CW, Nok A, Mullen AB, McFarlane E. DNA vaccination against the parasite enzyme gamma-glutamylcysteine synthetase confers protection against Leishmania donovani infec tion. Vaccine 2007; 25: 4502-9.
103. Titus RG, Gueiros-Filho FJ, de Freitas LA, Beverley SM. Development of a safe live Leishmania vaccine line by gene replacement. Proc Natl Acad Sci USA 1995; 92: 10267-71.
104. Amaral VF, Teva A, Oliveira-Neto MP, Silva AJ, Pereira MS, Cupolillo E, et al. Study of the safety, immuno genicity and efficacy of attenuated and killed Leishma nia major vaccines in a rhesus monkey (Macaca mulat ta) model of the human disease. Mem Inst Oswaldo Cruz 2002; 97: 1041-8.
105. Saravia NG, Escorcia B, Osorio Y, Valderrama L, Brooks D, Arteaga L, et al. Pathogenicity and protective immunogenicity of cysteine proteinase-deficient mutants of Leishmania mexicana in non-murine models. Vaccine 2006; 24: 4247-59.
106. Uzonna JE, Spath GF, Beverley SM, Scott P. Vaccina tion with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response. J Immunol 2004; 172: 3793-7.
107. Spath GF, Lye LF, Segawa H, Turco SJ, Beverley SM. Identification of a compensatory mutant (lpg2-REV) of Leishmania major able to survive as amastigotes within macrophages without LPG2-dependent glycoconjugates and its significance to virulence and immunization strat egies. Infect Immun 2004; 72: 3622-7.
108. Selvapandiyan A, Debrabant A, Duncan R, Muller J, Salotra P, Sreenivas G, et al. Centrin gene disruption impairs stage-specific basal body duplication and cell cycle progression in Leishmania. J Biol Chem 2004; 279: 25703-10.
109. Selvapandiyan A, Dey R, Nylen S, Duncan R, Sacks D, Nakhasi HL. Intracellular replication-deficient Leish mania donovani induces long lasting protective im munity against visceral leishmaniasis. J Immunol 2009; 183: 1813-20.
110. Selvapandiyan A, Dey R, Gannavaram S, Lakhal-Naouar I, Duncan R, Salotra P, et al. Immunity to visceral Leishmaniasis using genetically defined live-attenuated parasites. J Trop Med 2012; 2012: 631460. [Epub ahead of print] PMID: 21912560
111. Kedzierski L, Curtis JM, Doherty PC, Handman E, Kedzierska K. Decreased IL-10 and IL-13 production and increased CD44hi T cell recruitment contribute to Leishmania major immunity induced by non-persistent parasites. Eur J Immunol 2008; 38: 3090-100.
112. Carrion J, Folgueira C, Soto M, Fresno M, Requena, JM. Leishmania infantum HSP70-II null mutant as candidate vaccine against leishmaniasis: a preliminary evaluation. Parasit Vect 2011; 4: 150-9.
113. Palatnik-de-Sousa C. Vaccines for leishmaniasis in the fore coming 25 years. Vaccine 2008; 26: 1709-24.
114. Dumas C, Muyombwe A, Roy G, Matte C, Ouellette M, Olivier M, et al. Recombinant Leishmania major secret ing biologically active granulocyte-macrophage colony stimulating factor survives poorly in macrophages in vitro and delays disease development in mice. Am Soc Microbiol 2003; 71: 6499-509.
115. Fishbein DB, Robinson LE. Rabies. New Engl J Med 1993; 329: 1632-8.
116. Sauret JM, Vilissova N. Human brucellosis. J Am Board Fam Pract 2002; 15: 401-6.
117. Biglino A, Bolla C, Concialdi E, Trisciuoglio A, Romano A, Ferroglio E. Asymptomatic Leishmania infan tum infection in an area of northwestern Italy (Piedmont region) where such infections are traditionally nonen demic. J Clin Microbiol 2010; 48: 131-6.
118. Schantz PM, Steurer FJ, Duprey ZH, Kurpel KP, Barr SC,Jackson JE, et al. Autochthonous visceral leishma niasis in dogs in North America. J Am Vet Med Assoc 2005; 226: 1316-22.
119. Ready PD. Leishmaniasis emergence in Europe. Euro Surveillance 2010; 15: 19505.
120. Baneth G, Shaw SE. Chemotherapy of canine leishmani osis. Vet Parasitol 2002; 106: 315-24.
121. Palatnik-de-Sousa CB, dos Santos WR, Franc JC, a-Silva, da Casta RT, Reis AB, et al. Impact of canine control on the epidemiology of canine and human visceral leishma niasis in Brazil. Am J Trop Med Hyg 2001; 65: 510-7.
122. Reithinger R, Coleman PG, Alexander B, Vieira EP, Assis G, Davies CR. Are insecticide-impregnated dog collars a feasible alternative to dog culling as a strategy for controlling canine visceral leishmaniasis in Brazil? Intern J Parasitol 2004; 34: 55-62.
123. Courtenay O, Quinnell RJ, Garcez LM, Shaw JJ, Dye C. Infectiousness in a cohort of Brazilian dogs: why culling fails to control visceral leishmaniasis in areas of high transmission. J Infect Dis 2002; 186: 1314-20.
124. Boggiatto PM, Ramer-Tait AE, Metz K, Kramer EE, Gibson-Corley K, Mullin K, et al. Immunologic indica tors of clinical progression during canine Leishmania infantum infection. Cl Vac Immunol 2010; 17: 267-73.
125. Poot J, Janssen LHM, van Kasteren-Westerneng TJ, van der Heijden-Liefkens KHA, Schijns VEJC, Heckeroth A. Vaccination of dogs with six different candidate leish maniasis vaccines composed of a chimerical recom binant protein containing ribosomal and histone protein epitopes in combination with different adjuvants. Vac cine 2009; 27: 4439-46.
126. Bahia D, Gontijo NF, León IR, Perales J, Pereira MH, Oliveira G, et al. Antibodies from dogs with canine vis ceral leishmaniasis recognise two proteins from the sa liva of Lutzomyia longipalpis. Parasitol Res 2007; 100: 449-54.
127. Giunchetti RC, Corrêa-Oliveira R, Martins-Filho OA, Teixeira-Carvalho A, Roatt BM, de Oliveira Aguiar-Soares RD, et al. A killed Leishmania vaccine with sand fly saliva extract and saponin adjuvant displays immu nogenicity in dogs. Vaccine 2008; 26: 623-38.
128. Gomes R, Teixeira C, Teixeira MJ, Oliveira F, Menezes MJ, Silva C, et al. Immunity to a salivary protein of a sand fly vector protects against the fatal outcome of vis ceral leishmaniasis in a hamster model. Proc Nat Ac Sc USA 2008; 105: 7845-50.
129. Collin N, Gomes R, Teixeira C, Cheng L, Laughinghouse A, Ward JM, et al. Sand fly salivary proteins induce strong cellular immunity in a natural reservoir of visceral leishmaniasis with adverse consequences for Leishmania," PLoS Pathogens 2009; 5: e1000441.
130. Dantas-Torres F. Leishmune vaccine: the newest tool for prevention and control of canine visceral leishmaniosis and its potential as a transmission-blocking vaccine. Vet Parasitol 2006; 141: 1-8.
131. da Silva VO, Borja-Cabrera GP, Correia Pontes NN, de Souza EP, Luz KG, Palatnik M, et al. A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amaranto, RN). Vaccine 2000; 19: 1082-92.
132. Nogueira FS, Moreira MA, Borja-Cabrera GP, Santos FN, Menz I, Parra LE, et al. Leishmune vaccine blocks the transmission of canine visceral leishmaniasis: ab sence of Leishmania parasites in blood, skin and lymph nodes of vaccinated exposed dogs," Vaccine 2005; 23: 4805-10.
133. Saraiva EM, de Figueiredo Barbosa A, Santos FN, Borja-Cabrera GP, Nico D, Souza LOP, et al. The FML vaccine (Leishmune) against canine visceral leishma niasis: a transmission blocking vaccine. Vaccine 2006; 24: 2423-31.
134. Borja-Cabrera GP, Cruz Mendes A, Paraguai de Souza E, Hashimoto Okada LY, de A Trivellato FA, Kawasaki JK, et al. Paraguai de Souza et al. Effective immuno therapy against canine visceral leishmaniasis with the FML-vaccine. Vaccine 2004; 22: 2234-43.
135. Borja-Cabrera GP, Santos FN, Santos FB, de Trivellato FAA, Kawasaki JKA, Costa AC, et al. Immunotherapy with the saponin enriched-Leishmune vaccine versus immunochemotherapy in dogs with natural canine vis ceral leishmaniasis. Vaccine 2010; 28: 597-603.
136. Palatnik-de-Sousa CB, Silva-Antunes I, Ade AM, Menz I, Palatnik M, Lavor C. Decrease of the incidence of human and canine visceral leishmaniasis after dog vac cination with Leishmune in Brazilian endemic areas. Vaccine 2009; 27: 3505-12.
137. Fernandes AP, Costa MM, Coelho EA, Michalick MS, de Freitas E, Melo MN, et al. Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein. Vaccine 2008; 26: 5888-95.
138. Resende DM, Caetano BC, Dutra MS, Penido ML, Abrantes CF, Verly RM, et al. Epitope mapping and protective immunity elicited by adenovirus expressing the Leishmania amastigote specific A2 antigen: correla tion with IFN-? and cytolytic activity by CD8+ T cells," Vaccine 2008; 26: 4585-93.
139. Trigo J, Abbehusen M, Netto EM, Nakatani M, Pedral-Sampaio G, de Jesus RS, et al. Treatment of canine visceral leishmaniasis by the vaccine Leish-111f +MPL-SE. Vaccine 2010; 28: 3333-40.
140. Daneshvar H, Molaei MM, Kamiabi H, Burchmore R, Hagan P, Phillips RS. Gentamicin-attenuated Leishma nia infantum: cellular immunity production and protec tion of dogs against experimental canine leishmaniasis. Parasit Immunol 2010; 32: 722-30.